Research published in The Lancet Diabetes & Endocrinology found that type 2 diabetes patients who took once-weekly albiglutide attained significant reductions in HbA1C levels, comparable with those who were on once-daily liraglutide. "The data indicate that albiglutide is a reasonable alternative to other glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of diabetes. It has good efficacy and a better tolerability profile with less nausea," said researcher Dr. Richard E. Pratley.

Related Summaries